Endoprotease 40 (E40)
Financiado
First ever preventive treatment for celiac disease and gluten sensitivity
E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.
Different from any other com...
E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.
Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD). The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten.
E40 will allow sufferers to manage inadvertent gluten exposure and will improve sufferer's Quality of Life, in particular allowing them to normalise their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, like eating in a restaurant, travelling and visiting their friends in their homes.
E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form. E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion: E40 gluten degradation leads to a gluten-free status (residual gluten<20ppm as per EC guidelines).
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2023-05-18
Fecha Fin: 2025-05-31
Fecha Fin: 2025-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-18
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
NEMYSIS LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
